M&A / Acquisition · Global ex-US · Announced 9 Aug 2026
Alfasigma → Nordic Pharma
M&A / Acquisition deal between Alfasigma (Italy) and Nordic Pharma (Netherlands), announced 9 Aug 2026.
Parties: Alfasigma S.p.A. (Italy) → Nordic Group B.V. (Netherlands)
- Deal type
- M&A / Acquisition
- Value
- See terms
- Territory
- Global acquisition; MENA relevance: Nordic registrations in UAE, Qatar, Algeria, Tunisia, Jordan; Alfasigma registrations in Tunisia, UAE, Iraq, Saudi, Kuwait, Lebanon, Jordan, Oman, Bahrain, Egypt
- Therapeutic area
- Multi-therapy
- Asset
- 100% of Nordic Group — rheumatology (Nordimet methotrexate franchise), women's health, critical care, ophthalmology (incl. Lacrifill); ~€190M 2025 revenue; 265 employees; direct operations in 18 countries plus Canada and Japan platforms
- Announced
- 9 Aug 2026
Our analysis
Why this matters
Italy's Alfasigma — built from the 2015 merger of Alfa Wassermann and Sigma-Tau, now ~€1.3B revenue, 4,000 employees, fresh from the $794M Intercept acquisition (2023) — is executing its third M&A move in three years to become a GI/immunology specialist with global reach. Nordic Group brings the Nordimet methotrexate franchise to pair with Alfasigma's Jyseleca (filgotinib), plus women's health, critical care and ophthalmology.
For CEOs: a European mid-cap is deliberately assembling a specialty portfolio MNCs are divesting from.
The full analysis is free to read with a work email on this page.
Source: Alfasigma PR